Olema [OLMA] vs Zymeworks [ZYME] Detailed Stock Comparison

Olema Pharmaceuticals Inc.

NASDAQ
Loading...

Zymeworks Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Olema Pharmaceuticals Inc. wins in 6 metrics, Zymeworks Inc. wins in 8 metrics, with 0 ties. Zymeworks Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Olema Pharmaceuticals Inc. Zymeworks Inc. Better
P/E Ratio (TTM) N/A 3.79 N/A
Price-to-Book Ratio 2.76 7.32 Olema Pharmaceuticals Inc.
Debt-to-Equity Ratio 0.88 6.80 Olema Pharmaceuticals Inc.
PEG Ratio -6.38 0.05 Zymeworks Inc.
EV/EBITDA -5.44 -20.40 Olema Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% -76.56% Olema Pharmaceuticals Inc.
Operating Margin (TTM) 0.00% -1,755.55% Olema Pharmaceuticals Inc.
Return on Equity -36.61% -26.72% Zymeworks Inc.
Return on Assets (TTM) -21.42% -14.29% Zymeworks Inc.
Free Cash Flow (TTM) $-146.72M $-35.36M Zymeworks Inc.
1-Year Return 149.81% 119.86% Olema Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) N/A 18.46 N/A
Enterprise Value $914.19M $1.73B Zymeworks Inc.
EV/Revenue Ratio N/A 16.33 N/A
Revenue per Share (TTM) N/A $1 N/A
Earnings per Share (Diluted) $-1.87 $-1.08 Zymeworks Inc.
Beta (Stock Volatility) 2.18 1.20 Zymeworks Inc.
Short % of Float 15.16% 8.16% Zymeworks Inc.

Olema Pharmaceuticals Inc. vs Zymeworks Inc. Stock Performance Analysis

Loading Price Chart...

OLMA
ZYME

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Olema Pharmaceuticals Inc.-1.68%-18.59%-28.16%-55.14%-61.43%-58.43%
Zymeworks Inc.1.00%-1.77%-9.07%-0.41%-7.13%-8.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Olema Pharmaceuticals Inc.149.81%132.63%-52.40%-73.03%-73.03%-73.03%
Zymeworks Inc.119.86%189.85%-20.78%93.31%93.31%93.31%

Performance & Financial Health Analysis: Olema Pharmaceuticals Inc. vs Zymeworks Inc.

MetricOLMAZYME
Market Information
Market Cap i$1.34B$1.96B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i879,756626,460
90 Day Avg. Volume i1,388,255729,503
Last Close$10.51$24.35
52 Week Range$3.89 - $36.26$11.51 - $29.75
% from 52W High-71.01%-18.15%
All-Time High$60.27 (Nov 30, 2020)$59.03 (Jan 11, 2021)
% from All-Time High-82.56%-58.75%
Growth Metrics
Quarterly Revenue GrowthN/A-0.92%
Quarterly Earnings GrowthN/A-0.92%
Financial Health
Profit Margin (TTM) i0.00%-0.77%
Operating Margin (TTM) i0.00%-17.56%
Return on Equity (TTM) i-0.37%-0.27%
Debt to Equity (MRQ) i0.886.80
Cash & Liquidity
Book Value per Share (MRQ)$5.88$3.60
Cash per Share (MRQ)$5.80$3.10
Operating Cash Flow (TTM) i$-146,716,000$-33,005,000
Levered Free Cash Flow (TTM) i$-82,896,248$-12,959,125
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Olema Pharmaceuticals Inc. vs Zymeworks Inc.

MetricOLMA (Apr 24, 2026)ZYME (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) iN/A3.79
Forward P/E i-6.3833.43
PEG Ratio i-6.380.05
Price to Sales (TTM) iN/A18.46
Price to Book (MRQ) i2.767.32
Market Capitalization
Market Capitalization i$1.34B$1.96B
Enterprise Value i$914.19M$1.73B
Enterprise Value Metrics
Enterprise to Revenue iN/A16.33
Enterprise to EBITDA i-5.44-20.40
Risk & Other Metrics
Beta i2.181.20
Book Value per Share (MRQ) i$5.88$3.60

Financial Statements Comparison: Olema Pharmaceuticals Inc. vs Zymeworks Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricOLMA (2025)ZYME (2025)
Revenue/Sales i0105.97M
Cost of Goods Sold iN/AN/A
COGS % of Revenue i-0.0%
Gross Profit iN/AN/A
Gross Margin i-0.0%
Research & Development i157.70M137.00M
Operating Income (EBIT) i-178.70M-92.54M
Operating Margin i--87.3%
EBITDA i-178.21M-80.82M
EBITDA Margin i--76.3%
Pre-Tax Income i-162.45M-79.75M
Pre-Tax Income % of Revenue i--75.3%
Income Tax iN/A1.38M
Income Tax % of Revenue i-1.3%
Net Income (Profit) i-162.45M-81.13M
Profit Margin i--76.6%

Balance Sheet & Liquidity Metrics

MetricOLMA (2025)ZYME (2025)
Cash & Equivalents i48.30M41.16M
Total Current Assets i515.45M248.77M
Total Current Assets % of Revenue i-234.8%
Total Current Liabilities i51.80M42.32M
Total Current Liabilities % of Revenue i-39.9%
Long-Term Debt i3.07M14.80M
Long-Term Debt % of Revenue i-14.0%
Total Shareholders Equity i478.56M268.50M
Retained Earnings i-597.56M-953.16M
Retained Earnings % of Revenue i--899.5%
Property, Plant & Equipment i1.42M29.56M

Cash Flow Statement Comparison

MetricOLMA (2025)ZYME (2025)
Operating Cash Flow i-141.30M-40.00M
Operating Cash Flow % of Revenue i--37.7%
Capital Expenditures i0-1.52M
Free Cash Flow i-146.72M-35.36M
FCF Margin i--33.4%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-41.70M

Short Interest & Institutional Ownership Analysis

MetricOLMAZYME
Shares Short i12.27M4.08M
Short Ratio i5.195.42
Short % of Float i15.16%8.16%
Shares Outstanding i81.38M75.19M
Float Shares i67.43M72.80M
% Held by Insiders i1.97%1.26%
% Held by Institutions i101.11%98.45%
% Held by Public i-3.08%0.29%

Dividend Analysis & Yield Comparison: Olema Pharmaceuticals Inc. vs Zymeworks Inc.

MetricOLMAZYME
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A